Investigators randomly assigned patients with STEMI and cardiogenic shock to receive the Impella CP plus standard care or standard care alone. The primary endpoint was death from any cause at 180 ...

confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5% ...

The RECOVER IV randomized trial of the Impella (Abiomed) mechanical circulatory device in patients with STEMI complicated by cardiogenic shock has been halted, its two principal investigators have ...

the trial showed that routine use of the Impella CP microaxial flow pump (Abiomed) lowered 6-month mortality in patients with STEMI complicated by cardiogenic shock compared with standard care. There ...

The analysis examined 143 consecutive patients with cardiogenic shock due to myocarditis who received Impella support or Impella plus VA ECMO support, known as ECpella. These patients are included ...

She also drew attention to the Impella trial that gave half of patients with MI-related cardiogenic shock a microaxial flow pump (Impella CP) in addition to standard of care. "This is another ...

“Our goal is for the Impella® platform to become the standard of care for cardiac recovery. We want to help as many patients in cardiogenic shock as possible to keep their own heart – with ...

The IABP, developed in the 1960s, was the first device to provide temporary mechanical support to the heart in patients with cardiogenic shock, Sacco said. Although other such devices have been ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular ...

WASHINGTON, D.C.—Johnson & Johnson MedTech’s Abiomed announced that its compressible, expandable heart pump has cleared a pivotal trial, and it’s now headed for FDA review in the coming months.

Get Instant Summarized Text (Gist) Early use of an intra-aortic balloon pump (IABP) in patients with cardiogenic shock due to heart failure did not improve 60-day survival or facilitate transition ...